Basal GLP-1 Levels in Morbidly Obese Patients following Biliopancreatic Diversion Surgery

2012 ◽  
Vol 61 (1) ◽  
pp. 70-73 ◽  
Author(s):  
Daniel de Luis ◽  
D. Pacheco ◽  
Rosa Conde ◽  
David Primo ◽  
Rocio Aller ◽  
...  
Keyword(s):  
Biliopancreatic Diversion ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Biliopancreatic Diversion Surgery

scholarly journals Biodistribution of the radiopharmaceutical sodium pertechnetate after biliopancreatic bypass with a duodenal switch

2007 ◽  
Vol 50 (spe) ◽  
pp. 189-197 ◽  
Author(s):  
Irami Araújo-Filho ◽  
Amália Cínthia Meneses Rêgo ◽  
José Brandão-Neto ◽  
Arthur Villarim-Neto ◽  
Eryvaldo Sócrates Tabosa Egito ◽  
...  
Keyword(s):  
Small Bowel ◽  
Biliopancreatic Diversion ◽  
Duodenal Switch ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Late Mortality ◽  
Biliopancreatic Bypass ◽  
Sodium Pertechnetate ◽  
Significant Difference

Study with the purpose to examine the effects of duodenal switch (DS), regularly performed in morbidly obese patients, on biodistribution of sodium pertechnetate in several organs of rats. There was no early or late mortality in either rats groups. The values of percent radioactivity per gram of tissue (%ATI/g), showed no significant difference in liver, stomach, small bowel, duodenum, kidney, heart, bladder, bone and brain, when compared the DS rats with sham and controls rats. A postoperative significant increase (p<0.05) in mean %ATI/g levels was observed in spleen, pancreas and muscle in group DS rats, as compared to group S and C rats. In the lung there was an increase and in thyroid a decrease in mean %ATI/g of DS rats, when compared to sham rats (p<0.05). In conclusion, the biliopancreatic diversion with duodenal switch in rats modified the biodistribution of sodium pertechnetate in thyroid, lung, pancreas, spleen and muscle.

Resistin Levels in Morbid Obese Patients Following the Biliopancreatic Diversion Surgery

2011 ◽  
Vol 43 (03) ◽  
pp. 205-208 ◽  
Author(s):  
D. A. de Luis ◽  
M. C. Terroba ◽  
L. Cuellar ◽  
R. Conde ◽  
D. Primo ◽  
...  
Keyword(s):  
Biliopancreatic Diversion ◽  
Obese Patients ◽  
Morbid Obese ◽  
Biliopancreatic Diversion Surgery

Incisional Hernia Prophylaxis in Morbidly Obese Patients Undergoing Biliopancreatic Diversion

2010 ◽  
Vol 21 (10) ◽  
pp. 1559-1563 ◽  
Author(s):  
Giuseppe Currò ◽  
Tommaso Centorrino ◽  
Cinzia Musolino ◽  
Giuseppe Sarra ◽  
Giuseppe Navarra
Keyword(s):  
Incisional Hernia ◽  
Biliopancreatic Diversion ◽  
Morbidly Obese ◽  
Obese Patients

Long-term clinical and functional impact of biliopancreatic diversion on type 2 diabetes in morbidly and non–morbidly obese patients

2016 ◽  
Vol 12 (4) ◽  
pp. 822-827 ◽  
Author(s):  
Nicola Scopinaro ◽  
Giovanni Camerini ◽  
Francesco Papadia ◽  
Gabriella Andraghetti ◽  
Renzo Cordera ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Biliopancreatic Diversion ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Functional Impact

Is laparoscopic single-stage biliopancreatic diversion with duodenal switch safe in super morbidly obese patients?

2014 ◽  
Vol 10 (3) ◽  
pp. 427-430 ◽  
Author(s):  
Masoud Rezvani ◽  
Iswanto Sucandy ◽  
Amarita Klar ◽  
Fernando Bonanni ◽  
Gintaras Antanavicius
Keyword(s):  
Biliopancreatic Diversion ◽  
Duodenal Switch ◽  
Single Stage ◽  
Morbidly Obese ◽  
Obese Patients

scholarly journals Glucose metabolism and incretins level in morbidly obese patients and in patients after biliopancreatic diversion performed for morbid obesity

2014 ◽  
Vol 11 (1) ◽  
pp. 24-31
Author(s):  
I I Dedov ◽  
G A Melnichenko ◽  
E A Troshina ◽  
N V Mazurina ◽  
N A Ogneva ◽  
...  
Keyword(s):  
Blood Glucose ◽  
Glucose Metabolism ◽  
Biliopancreatic Diversion ◽  
Plasma Insulin ◽  
Fasting Glucose ◽  
Morbidly Obese ◽  
Obese Patients ◽  
Insulin Levels ◽  
Glucose Levels ◽  
Blood Glucose Levels

We’ve studied a carbohydrate metabolism in morbidly obese (MO) patients and the patients after bariatric surgery. The patients of the 1st group had BMI40 (n=22) and no history of diabetes mellitus. Patients after biliopancreatic diversion (BPD) performed for MO were included in the 2nd group (n=23). The 3rd group was a control group of normal weight healthy subjects (n=22). Blood glucose levels, insulin, GLP-1, GIP and glucagon during the OGTT (with 75 g of glucose) at 0, 30, 60 and 120 minutes were measured in all patients. In MO group fasting glucose levels were the highest. Impaired glucose metabolism was revealed in 68.2% of patients (n=10). Impaired fasting glucose (IFG) was diagnosed in 4 cases (18.2%), impaired glucose tolerance (IGT) in 11 patients (50%). In the BPD postprandial blood glucose levels (120 min) were lower if compared to the other groups. In 4 individuals (17.4%) we found postprandial hypoglycemia (2.8 mmol/l). Patients of the MO group had the highest fasting insulin levels and HOMA-IR (p0.001). The maximum of insulin concentration was seen on minute 30 of the OGTT in the 2nd and 3rd groups, and it was significantly higher in the post-bariatric patients (p=0.026). In MO group the maximum of the plasma insulin levels were on the 60th minute and were still elevated after 120 minutes. Fasting and stimulated (on the 30th minute) levels of GLP-1 were significantly higher after BPD (р=0.037 and p=0.022 at 0 and 30 min, respectively). Morbidly obese patients had higher fasting and stimulated GIP. Fasting glucagon concentrations were similar in the surgical and control groups, while the people with MO had higher initial levels of glucagon (p=0.013) and it was not suppressed during the OGTT (p=0.076). Glucose intolerance and insulin resistance incidence was higher in MO patients. Hyperglucagonemia, increased GIP and decreased GLP-1 levels are observed in MO patients. Stimulated plasma insulin and GLP-1 concentrations were significantly increased in patients who underwent BPD, and may cause postprandial hypoglycemia.

Sign in / Sign up

Export Citation Format

Share Document